Developer docs
API playgroundTry for free, no card

Search company profiles

iVeena

Full company profile

uuid0002jzi

Namestring
iVeena
Legal namestring
iVeena Delivery Systems, Inc.
Websiteurl
iveenamed.com
Company typeenum
Private
Founded yearint
2015
Descriptiontext

iVeena Delivery Systems, Inc. is a privately held, clinical-stage ophthalmology biopharmaceutical company founded in 2015 as a spin-out from the University of Utah's Moran Eye Center, headquartered in Salt Lake City, Utah. The company develops disease-modifying pharmacologic therapies for refractive eye diseases, anchored by a proprietary platform based on lysyl oxidase (LOX) enzyme activation that strengthens collagen crosslinks in scleral and corneal tissues. Its lead programs include IVMED-85, a first-in-class, preservative-free, non-atropine daily eye drop for pediatric myopia currently in Phase 1 clinical trials, and IVMED-80, an FDA Orphan Drug Designated daily eye drop for keratoconus that has been exclusively licensed globally to Glaukos Corporation. Additional pipeline assets include IVMED-10 and IVMED-20 sustained-release dexamethasone implants placed in the lens capsule during cataract surgery, and IVMED-95 for adult low myopia.

iVeena's underlying technology spans two distinct approaches: the LOX activation platform (IVMED-80, IVMED-85, IVMED-95) for disease modification in refractive conditions, and an intracapsular drug delivery platform licensed from the University of Utah that uses the lens capsule as a reservoir to deliver medication to both anterior and posterior eye segments. Patent protection on IVMED-80 compositions and formulations extends through at least 2041, and Phase 1/2a clinical data demonstrated a 1.8D mean reduction in Kmax and 11.3-letter BCVA improvement in keratoconus patients with no treatment-related adverse events.

The company operates a capital-efficient out-licensing business model, developing clinical-stage assets through proof-of-concept milestones before partnering with larger pharmaceutical companies for commercialization. Its primary revenue mechanism is licensing royalties and milestone payments, anchored by the 2022 Glaukos agreement which delivered a $10M upfront payment with potential for up to $90M in development and sales milestones plus royalties. The company supplements equity financing with non-dilutive federal grants from NIH/NEI and NSF, having secured over $2.6M in SBIR awards. Target customers are patients with progressive pediatric myopia, keratoconus, and post-cataract surgical inflammation, served indirectly through licensing partners rather than direct sales.

Short descriptiontext

iVeena Delivery Systems is a clinical-stage ophthalmology biopharmaceutical company developing disease-modifying eye drops and sustained-release implants for pediatric myopia, keratoconus, and post-cataract inflammation, using a proprietary LOX enzyme activation platform licensed out to partners like Glaukos Corporation.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersSalt Lake City, United States
HQ citystring
Salt Lake City
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
ocular drug delivery, ophthalmic pharmaceuticals, keratoconus treatment, myopia control eye drops, intracapsular drug implants
Industry3 codes
PRIMARYHLAIAAAL
Ophthalmology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAHAJAH
Cataract Surgery Systems & IOLs (Phaco Systems, IOLs, Intraoperative Aberrometry, Viscoelastics)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Ophthalmic Devices (Vision Care & Surgical)
SECONDARYHLAHAIAL
Ocular Drug Delivery Devices (Eye Droppers/Inserts)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Drug Delivery Devices (Injectors, Pumps, Inhalers)
NAICS code2 codes
  • Ophthalmic Goods Manufacturing339115
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Surgical & Medical Instruments & Apparatus3841
Product category
Ophthalmic Pharmaceuticals
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Licensing Royalties
TypeLicensing Royalties
Description

iVeena licenses its developed products to pharmaceutical marketing partners. The IVMED-80 licensing agreement with Glaukos Corporation includes $10M upfront payment, potential development and sales milestone payments, and royalties on sales.

iveenamed.com
2Non-dilutive Grant Funding
TypeProfessional Services
Description

The company secures NIH, NEI, and NSF SBIR grants to fund development activities, including $3M Series B-2 financing and various federal grants totaling over $2M.

iveenamed.com
3Future Product Licensing
TypeLicensing Royalties
Description

Company structured to develop candidates through clinical trials then out-license to pharmaceutical partners for commercialization.

iveenamed.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

iVeena develops disease-modifying pharmacologic ophthalmic products, including investigational eye drops (IVMED-85 for pediatric myopia, IVMED-80 for keratoconus) and bioerodable intracapsular dexamethasone implants (IVMED-10 and IVMED-20) for post-cataract inflammation. The company operates as a clinical-stage biopharmaceutical firm that advances proprietary candidates through clinical trials and out-licenses them to pharmaceutical marketing partners for commercialization.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Phase 1/2a IVMED-80 trial: 1.8D mean reduction in Kmax, 11.3 letter BCVA improvement, no treatment-related adverse events
+2 more records
Product overview1 text field

iVeena Delivery Systems is a privately held, clinical-stage ophthalmology company developing disease-modifying pharmacologic innovations for refractive eye diseases. The company operates a platform of novel proprietary eye drops with lead programs IVMED-85 (pediatric myopia) and IVMED-80 (keratoconus, licensed to Glaukos). Additional pipeline includes IVMED-10 and IVMED-20 (sustained-release dexamethasone implants for post-cataract inflammation), and IVMED-95 (adult low myopia). The company also developed an intracapsular drug delivery platform technology for anterior and posterior eye segment medication delivery.

Product and service2 records
1IVMED-85
CategoryOphthalmic eye drop - myopia
Description

First-in-class, preservative-free, non-surgical, non-invasive, non-atropine daily prescription eye drop for pediatric myopia that strengthens scleral and corneal collagen crosslinks through lysyl oxidase (LOX) activation to prevent myopic progression and decrease axial elongation rate. IND submitted to the FDA in June 2025.

2IVMED-80
Scale indicator10 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2022-08-24
Description

Strategic licensing agreement granting Glaukos Corporation exclusive global license to develop and commercialize IVMED-80 for keratoconus treatment. Glaukos paid $10 million upfront and assumes all costs for development and regulatory activities. Deal terms include development and sales milestone payments plus royalties on sales.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Technology licensed from University of Utah Moran Eye Center. Company was formed to commercialize technology from this institution. Dr. Balamurali Ambati and Dr. Sarah Molokhia have affiliations with the University of Utah.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Market position
Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles12 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds7 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors5 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

iVeena

Ophthalmic Pharmaceuticalsiveenamed.com

iVeena Delivery Systems is a clinical-stage ophthalmology biopharmaceutical company developing disease-modifying eye drops and sustained-release implants for pediatric myopia, keratoconus, and post-cataract inflammation, using a proprietary LOX enzyme activation platform licensed out to partners like Glaukos Corporation.

What iVeena does

iVeena Delivery Systems, Inc. is a privately held, clinical-stage ophthalmology biopharmaceutical company founded in 2015 as a spin-out from the University of Utah's Moran Eye Center, headquartered in Salt Lake City, Utah. The company develops disease-modifying pharmacologic therapies for refractive eye diseases, anchored by a proprietary platform based on lysyl oxidase (LOX) enzyme activation that strengthens collagen crosslinks in scleral and corneal tissues. Its lead programs include IVMED-85, a first-in-class, preservative-free, non-atropine daily eye drop for pediatric myopia currently in Phase 1 clinical trials, and IVMED-80, an FDA Orphan Drug Designated daily eye drop for keratoconus that has been exclusively licensed globally to Glaukos Corporation. Additional pipeline assets include IVMED-10 and IVMED-20 sustained-release dexamethasone implants placed in the lens capsule during cataract surgery, and IVMED-95 for adult low myopia.

iVeena's underlying technology spans two distinct approaches: the LOX activation platform (IVMED-80, IVMED-85, IVMED-95) for disease modification in refractive conditions, and an intracapsular drug delivery platform licensed from the University of Utah that uses the lens capsule as a reservoir to deliver medication to both anterior and posterior eye segments. Patent protection on IVMED-80 compositions and formulations extends through at least 2041, and Phase 1/2a clinical data demonstrated a 1.8D mean reduction in Kmax and 11.3-letter BCVA improvement in keratoconus patients with no treatment-related adverse events.

The company operates a capital-efficient out-licensing business model, developing clinical-stage assets through proof-of-concept milestones before partnering with larger pharmaceutical companies for commercialization. Its primary revenue mechanism is licensing royalties and milestone payments, anchored by the 2022 Glaukos agreement which delivered a $10M upfront payment with potential for up to $90M in development and sales milestones plus royalties. The company supplements equity financing with non-dilutive federal grants from NIH/NEI and NSF, having secured over $2.6M in SBIR awards. Target customers are patients with progressive pediatric myopia, keratoconus, and post-cataract surgical inflammation, served indirectly through licensing partners rather than direct sales.

iVeena firmographics

Firmographics
Name
iVeena
Legal name
iVeena Delivery Systems, Inc.
Website
https://iveenamed.com
Company type
Private
Founded year
2015
Operating status
Operating
Headcount range
1–10 employees
Short description
iVeena Delivery Systems is a clinical-stage ophthalmology biopharmaceutical company developing disease-modifying eye drops and sustained-release implants for pediatric myopia, keratoconus, and post-cataract inflammation, using a proprietary LOX enzyme activation platform licensed out to partners like Glaukos Corporation.
Ownership category
akta.pro rank

iVeena industry classification

Industry
Product category
Ophthalmic Pharmaceuticals
NAICS
Ophthalmic Goods Manufacturing (339115), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
SIC
Pharmaceutical Preparations (2834), Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAIAAAL
Ophthalmology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAHAJAH
Cataract Surgery Systems & IOLs (Phaco Systems, IOLs, Intraoperative Aberrometry, Viscoelastics)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Ophthalmic Devices (Vision Care & Surgical)
SECONDARYHLAHAIAL
Ocular Drug Delivery Devices (Eye Droppers/Inserts)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Drug Delivery Devices (Injectors, Pumps, Inhalers)

Keywords

  • Ocular drug delivery
  • Ophthalmic pharmaceuticals
  • Keratoconus treatment
  • Myopia control eye drops
  • Intracapsular drug implants

Where iVeena is headquartered

Location

Headquarters

HQ city
Salt Lake City
HQ country
United States
HQ region
North America

Offices1 record

Markets served

iVeena business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Licensing Royalties: iVeena licenses its developed products to pharmaceutical marketing partners. The IVMED-80 licensing agreement with Glaukos Corporation includes $10M upfront payment, potential development and sales milestone payments, and royalties on sales.
  2. Non-dilutive Grant Funding: The company secures NIH, NEI, and NSF SBIR grants to fund development activities, including $3M Series B-2 financing and various federal grants totaling over $2M.
  3. Future Product Licensing: Company structured to develop candidates through clinical trials then out-license to pharmaceutical partners for commercialization.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels5 records

iVeena product offering

Product offering

Core offering

iVeena develops disease-modifying pharmacologic ophthalmic products, including investigational eye drops (IVMED-85 for pediatric myopia, IVMED-80 for keratoconus) and bioerodable intracapsular dexamethasone implants (IVMED-10 and IVMED-20) for post-cataract inflammation. The company operates as a clinical-stage biopharmaceutical firm that advances proprietary candidates through clinical trials and out-licenses them to pharmaceutical marketing partners for commercialization.

Product overview

iVeena Delivery Systems is a privately held, clinical-stage ophthalmology company developing disease-modifying pharmacologic innovations for refractive eye diseases. The company operates a platform of novel proprietary eye drops with lead programs IVMED-85 (pediatric myopia) and IVMED-80 (keratoconus, licensed to Glaukos). Additional pipeline includes IVMED-10 and IVMED-20 (sustained-release dexamethasone implants for post-cataract inflammation), and IVMED-95 (adult low myopia). The company also developed an intracapsular drug delivery platform technology for anterior and posterior eye segment medication delivery.

Differentiator

Problem solved

Functional benefit

Products and services

  • IVMED-85 First-in-class, preservative-free, non-surgical, non-invasive, non-atropine daily prescription eye drop for pediatric myopia that strengthens scleral and corneal collagen crosslinks through lysyl oxidase (LOX) activation to prevent myopic progression and decrease axial elongation rate. IND submitted to the FDA in June 2025.
  • IVMED-80

Quantifiable outcome

  • Phase 1/2a IVMED-80 trial: 1.8D mean reduction in Kmax, 11.3 letter BCVA improvement, no treatment-related adverse events
  • +2 more outcomes

Companies that use iVeena

Customer profile

Segments3 records

Ideal customer profiles2 records

iVeena technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

iVeena partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • Glaukos CorporationcoreOEM/ Whitelabel/ Licensing Partner · 24 August 2022Strategic licensing agreement granting Glaukos Corporation exclusive global license to develop and commercialize IVMED-80 for keratoconus treatment. Glaukos paid $10 million upfront and assumes all costs for development and regulatory activities. Deal terms include development and sales milestone payments plus royalties on sales.
  • University of Utah / Moran Eye CentercoreStrategic or Co-development PartnerTechnology licensed from University of Utah Moran Eye Center. Company was formed to commercialize technology from this institution. Dr. Balamurali Ambati and Dr. Sarah Molokhia have affiliations with the University of Utah.

Scale indicators10 records

Recent moves6 records

Expansion highlights5 records

iVeena competitors and assessment

Company assessment

Market position

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

iVeena social profiles

Digital presence

iVeena compliance and trust

Trust signal

Compliance1 record

iVeena financial estimates

Financial estimate

Revenue estimate

Valuation estimate

iVeena leadership team

Management profile

Number of profiles

Profiles12 records

iVeena funding detail

Funding detail

Funding overview

Funding rounds7 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

iVeena M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about iVeena

What does iVeena do?

iVeena develops disease-modifying pharmacologic ophthalmic products, including investigational eye drops (IVMED-85 for pediatric myopia, IVMED-80 for keratoconus) and bioerodable intracapsular dexamethasone implants (IVMED-10 and IVMED-20) for post-cataract inflammation. The company operates as a clinical-stage biopharmaceutical firm that advances proprietary candidates through clinical trials and out-licenses them to pharmaceutical marketing partners for commercialization.

Is iVeena a public or private company?

iVeena is a private company. It is classified as venture growth investor backed and is currently operating.

When was iVeena founded?

iVeena was founded in 2015. It employs 1 to 10 people.

Where is iVeena based?

iVeena is headquartered in Salt Lake City, United States, in the North America region.

How does iVeena make money?

Three revenue lines are on record. Licensing Royalties are the primary driver. The others are non-dilutive Grant Funding and future Product Licensing.

Does iVeena have an API?

No public API is recorded for iVeena.

What industry is iVeena in?

iVeena's product category is Ophthalmic Pharmaceuticals. Its primary akta.pro industry code is HLAIAAAL, Ophthalmology Pharmaceuticals, with a secondary code of HLAHAJAH, Cataract Surgery Systems & IOLs (Phaco Systems, IOLs, Intraoperative Aberrometry, Viscoelastics). Its NAICS code is 339115 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Optometry TimesiVeena submits IND to FDA for a phase 2 clinical trial for pediatric myopiaiVeena Delivery Systems has submitted an investigational new drug (IND) application to the FDA for IVMED-85, a novel eye drop aimed at preventing the progression of pediatric myopia. This drug employs a unique mechanism to improve refraction and decrease axial elongation, addressing a significant unmet medical need. If the FDA review is positive, iVeena plans to begin a multinational clinical trial in 2025.FinancialContent Business PageiVeena Delivery Systems Announces Positive End-of-Phase 1 FDA Meeting for IVMED-85iVeena Delivery Systems announced a successful End-of-Phase 1 Type B meeting with the U.S. FDA for IVMED-85, an investigational eye drop for pediatric myopia treatment. The FDA confirmed that Phase 1 clinical data and completed nonclinical toxicology support advancement into pediatric Phase 2 clinical development. The agency also provided alignment on key Phase 2 elements including study design, efficacy endpoints, and overall development strategy, giving iVeena a clear regulatory framework for finalizing its Phase 2 protocol.FinancialContent Business PageiVeena Delivery Systems Announces Successful Completion of Phase 1 Clinical Study of IVMED-85iVeena Delivery Systems announced successful completion of its Phase 1 clinical trial evaluating IVMED-85, an investigational preservative-free ophthalmic solution for pediatric myopia, with all 36 randomized healthy adult volunteers completing the six-week study. The trial demonstrated a favorable safety profile with no serious adverse events or clinically significant changes in visual or ocular measures, supporting advancement to Phase 2 clinical evaluation in children with progressive myopia. The company is actively preparing for continued FDA interactions and its Phase 2 pediatric clinical program to evaluate dosing, safety, and efficacy.Business Wire BlogiVeena Delivery Systems Announces Successful Completion of Phase 1 Clinical Study of IVMED-85iVeena Delivery Systems, Inc. announced the successful completion of a Phase 1 clinical trial for IVMED-85, a new ophthalmic solution aimed at treating pediatric myopia. The study, which involved 36 healthy adult volunteers, showed a favorable safety and tolerability profile, supporting advancement into Phase 2 trials. iVeena is now preparing for further clinical evaluations and interactions with the U.S. Food and Drug Administration.AijourniVeena Delivery Systems Announces First Patient Dosed in Phase 1 Study of IVMED-85 in Healthy Adult VolunteersiVeena Delivery Systems announced that the first participant has been dosed in its Phase 1 first-in-human clinical study of IVMED-85, an investigational eye drop for preventing myopic progression, in healthy adult volunteers. The randomized, controlled trial will evaluate safety and tolerability of twice daily dosing, with enrollment ongoing and dosing expected to complete in Q2 2026 and full readout in mid-Q3 2026. The company plans to use insights from this trial to design a Phase 2 study in children with progressive myopia, scheduled to begin in H2 2026.AijourniVeena Delivery Systems Announces Strategic Leadership Promotions to Accelerate Growth and Scientific InnovationiVeena Delivery Systems announced executive promotions, elevating Michael Burr to Chief Operating Officer and Sarah Molokhia to Chief Scientific Officer, as the company prepares to advance its lead asset IVMED-85 into Phase 1 clinical studies for pediatric myopia. The promotions coincide with an anticipated Phase 1 study initiation targeting enrollment beginning in February 2026, following positive FDA engagement that resulted in an open investigational new drug (IND) application. The company credited the new leaders' contributions to prior milestones including financing rounds, regulatory submissions, and a licensing agreement with Glaukos Corporation.Business Wire BlogiVeena Delivery Systems Announces Strategic Leadership Promotions to Accelerate Growth and Scientific InnovationiVeena Delivery Systems announced executive promotions, with Michael Burr elevated to Chief Operating Officer and Sarah Molokhia promoted to Chief Scientific Officer, while longtime COO Ned Weinshenker transitions to Vice President of Chemistry, Manufacturing, & Controls. The strategic realignment coincides with the anticipated Phase 1 study initiation for IVMED-85, the company's first-in-class investigational eye drop for pediatric myopia, with enrollment expected to begin in February 2026. These changes position the clinical-stage ophthalmology company to advance its disease-modifying therapies as it enters the clinical phase of product development.Venture Capital Access OnlineiVeena Closes Series B Financing to Advance Multiple Programs in Clinical DevelopmentiVeena closed a Series B preferred stock bridge financing round and received a SBIR Phase II grant from the National Eye Institute to advance its clinical development programs. The funding will be used to prepare for registration trials for keratoconus treatment and initiate pilot studies for pediatric high myopia and adult low myopia.Business Wire BlogiVeena Delivery Systems Announces Positive End-of-Phase 1 FDA Meeting for IVMED-85iVeena Delivery Systems, Inc. announced a successful End-of-Phase 1 meeting with the FDA for IVMED-85, a treatment for pediatric myopia. The FDA's feedback supports the advancement of IVMED-85 into Phase 2 clinical development, providing alignment on key elements of the development program. This milestone is seen as a significant step forward for iVeena as it moves toward the next stage of clinical trials.Eyes On EyecareiVeena submits IND to FDA for pediatric myopia clinical trialiVeena Delivery Systems Inc. has submitted an investigational new drug (IND) application to the FDA for its pediatric myopia candidate IVMED-85. This eye drop is designed to treat myopia through biochemical mechanisms involving collagen crosslinking and aims to initiate a multinational phase 2 study pending FDA approval. The IND submission is a crucial step in the clinical trial process as it requires FDA evaluation of safety and scientific rigor before any human trials can commence.